Oncolyze

Executive Summary

Oncolyze is a preclinical-stage biopharmaceutical company developing a novel class of cancer therapeutics that selectively disrupt cancer cell membranes. Its lead candidate, OM-301, is a fusion peptide targeting acute myelogenous leukemia (AML) and cancer stem cells. The company's unique mechanism of action offers potential advantages over traditional therapies by physically destroying cancer cells while sparing healthy cells, which could address resistance and relapse challenges in AML. Founded in 2020 and based in San Diego, Oncolyze is poised to advance OM-301 through preclinical development towards an Investigational New Drug (IND) application. The company's focus on a high-unmet-need indication and its differentiated approach position it for potential academic and industry partnerships. However, as a preclinical entity with no disclosed funding, it faces typical early-stage risks including capital requirements and clinical validation hurdles.

Upcoming Catalysts (preview)

• Q4 2026IND-Enabling Studies Initiation60% success
• Q2 2026Preclinical Proof-of-Concept Data in AML Models70% success
• Q3 2026Potential Seed/Series A Financing Announcement50% success